Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 14

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 14
---
x 3.7x 3.9x Average 4.4x 10%+ 15%+ 10%+ ~5% ~8% Transaction value as multiple of LTM sales TBD 1.5 5.4x Mid - single digits Source: Public Filings, CapIQ

20 Proposed merger supported by expert independent analyst community covering the Company

21 Alcon is confident that no higher offer exists Alcon encourages the STAAR Board of Directors to adopt a “go - shop” period to put aside any doubts that a higher offer exists ▪ Given the niche nature of ICLs, the high concentration of sales in China, and the long - term headwinds facing STAAR, no other strategic or financial buyer exists who, in the foreseeable future, would pay more than $28 per share ▪ Alcon is so confident that it has taken the unusual step to encourage the STAAR board to run an unencumbered go - shop process where Alcon will waive its matching rights and forgo any break - up fee if a superior proposal materializes No Competing Proposals over past decade ▪ As STAAR has disclosed, other than Alcon, no potential buyer has made an offer to purchase STAAR in the past decade

22 1. Alcon estimates STAAR doesn't have the scale or resources to be a profitable, high - growth standalone company Business fundamentals have materially changed since Alcon's initial offer in October 2024 and the adjustment in value is appropriate given true product demand – the market made that adjustment correctly Alcon, as the global leader in eye care, is best suited to maximize the value of this product – which is reflected in the premium offered Alcon is only acquiror to make an offer in the past decade; proposed “go - shop” period is expected to confirm Ability for existing stockholders to realize value consistent with Alcon's offer is highly uncertain Proposed Alcon transaction is in the best interest of STAAR and its stockholders 1